Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is featured in a BioMedWire editorial that examines the urgent need for innovative approaches to treating multiple sclerosis (MS), a progressive neurological disease affecting over 2.9 million people worldwide. The editorial, titled “The Quest to Repair What Multiple Sclerosis Takes Away,” highlights the limitations of current therapies, which can only slow disease progression but cannot stop it or reverse damage.
Current MS treatments focus on managing symptoms and reducing relapses, but they do not address the underlying cause: damage to the myelin sheath, the protective covering of nerve fibers. As the disease progresses, patients often experience worsening disability, including loss of mobility, vision problems, and cognitive decline. This unmet medical need underscores the importance of developing therapies that can repair myelin and restore function.
Quantum BioPharma is developing Lucid-MS, a patented, first-in-class drug candidate designed to directly target and repair the myelin sheath damaged by MS. The company announced that Lucid-MS is preparing to advance into Phase 2 clinical trials. In preclinical models, the compound has shown the ability to prevent and reverse myelin degradation, the underlying mechanism of MS. If successful, Lucid-MS could represent a paradigm shift in MS treatment, moving from symptom management to disease modification and repair.
The editorial notes that Quantum BioPharma’s approach is particularly significant because it addresses the root cause of disability in MS. By promoting remyelination, Lucid-MS has the potential to not only halt disease progression but also restore lost function, improving quality of life for millions of patients. The company’s focus on neurodegenerative and metabolic disorders, along with alcohol misuse disorders, positions it to address multiple high-need areas.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets an over-the-counter version of its UNBUZZD(TM) product, and receives royalty payments from sales.
The full press release is available at https://ibn.fm/WikKX. For more information about Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
